Introduction: Patients with chronic obstructive pulmonary disease (COPD) increasingly
receive combination bronchodilator therapies. Real world evidence for the benefits of …

Background: This study compared real-world patient-reported outcomes (PROs) measured
by the Clinical COPD Questionnaire (CCQ), the London Chest Activities of Daily Living …

Background No observational studies have evaluated the “real-world” effectiveness of dual
bronchodilation comprising a long-acting β2-agonist plus a long-acting muscarinic …

New guidelines emphasize combination bronchodilators as a mainstay of therapy for many
patients with symptomatic COPD and there are several new combination bronchodilator …

Background: Chronic obstructive pulmonary disease (COPD) guidelines recommend both
long-acting and dual bronchodilator therapy. It is unclear if there are differences in efficacy …

The incidence of chronic obstructive pulmonary disease (COPD) is rising in the United
States, and the disease represents a significant source of morbidity and mortality. Primary …

Rationale: There is uncertainty on the use of using triple therapy (inhaled
corticosteroids/long-acting β-agonist/long-acting muscarinic antagonist) inhaler therapy for …

Background Several new fixed-dose combination bronchodilators have been recently
launched, and assessing their efficacy relative to each other, and with open dual …

Randomized trials of triple therapy including an inhaled corticosteroid (ICS) for chronic
obstructive pulmonary disease (COPD) reported remarkable benefits on mortality compared …

Background The clinical guideline recommends use of long-acting β2 agonists/long-acting
muscarinic antagonists (LABA/LAMA) or long-acting β2 agonists/inhaled corticosteroids …